![Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists | SpringerLink Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40263-020-00789-3/MediaObjects/40263_2020_789_Fig1_HTML.png)
Application of Real-World Data and the REWARD Framework to Detect Unknown Benefits of Memantine and Identify Potential Disease Targets for New NMDA Receptor Antagonists | SpringerLink
![PDF] High-Dose Donepezil or Memantine: Next Step for Alzheimer's Disease? Larger Dosages May Benefit Patients Who Have 'Maxed Out' Existing Therapies | Semantic Scholar PDF] High-Dose Donepezil or Memantine: Next Step for Alzheimer's Disease? Larger Dosages May Benefit Patients Who Have 'Maxed Out' Existing Therapies | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b15d42c0bd4815bdf03544d13e163934bf0646c5/2-Table1-1.png)
PDF] High-Dose Donepezil or Memantine: Next Step for Alzheimer's Disease? Larger Dosages May Benefit Patients Who Have 'Maxed Out' Existing Therapies | Semantic Scholar
![Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy | Alzheimer's Research & Therapy | Full Text Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy | Alzheimer's Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Falzrt160/MediaObjects/13195_2012_Article_134_Fig2_HTML.jpg)